Spectrascience's Stock Collapse Leaves Investors in Regulatory Limbo
Spectrascience's shares have been pushed off major exchanges and now trade only on over-the-counter (OTC) platforms. The move follows years of financial reporting failures and regulatory scrutiny. Without up-to-date disclosures, investors struggle to assess the company's true value. The U.S. Securities and Exchange Commission (SEC) first suspended trading of Spectrascience's stock in February 2021. The regulator cited concerns over the company's disclosure practices and its failure to file financial reports since 2017. This led to a permanent ban from regulated exchanges, forcing shares onto OTC markets where price transparency is limited.
Investors have since filed private class-action lawsuits against the company. These claims, dating from March to September 2022, allege securities fraud tied to misleading statements about the Pinnacle Study for poziotinib. Lead plaintiff deadlines in these cases extend to September 2025. Meanwhile, the company merged with Assertio Holdings, resulting in its delisting.
Despite operating in a high-growth cancer-detection sector, Spectrascience has been unable to leverage its technology. The lack of financial disclosures makes it nearly impossible for investors to determine a fair share price. While no recent SEC enforcement actions have been recorded, the agency could still revoke the company's registration entirely, ending public trading for good. Spectrascience currently faces no formal restructuring, liquidation, or sale plans. Its shares remain in regulatory limbo, with OTC trading offering little clarity. The company's future hinges on resolving its long-standing reporting issues—or risking a complete removal from public markets.
